General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention. Policies impacting Cardiovascular and bone health. Pharmacy benefit manager reform proposals. FDA reform, prescription drug reimportation and new proposals.
2025 · 4th Quarter (Oct 1 - Dec 31)
AMGEN, INC.
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- AMGEN, INC.
- Filing UUID
- 731b015b-a00f-466c-b546-7a4b0b385896
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare Part D and Medicare Part B drug reimbursement, policies around MFN drug pricing, Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act" implementation, coverage and access for biosimilars.
Literal federal measure citations: H.R. 1
Tax issues related to the pharmaceutical industry. Implementation of PL 119-21.
Policies impacting disease prevention.
Issues related to antitrust legislation.
Issues related to patent protections.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.